دورية أكاديمية

Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study

التفاصيل البيبلوغرافية
العنوان: Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study
المؤلفون: Matsumura, Itaru, Ohtake, Shigeki, Atsuta, Yoshiko, Kurata, Mio, Minami, Yosuke, Takahashi, Naoto, Nakaseko, Chiaki, Iriyama, Noriyoshi, Fujimaki, Katsumichi, Kakihana, Kazuhiko, Ogasawara, Yoji, Ono, Takaaki, Okada, Masaya, Tauchi, Tetsuzo, Miyamoto, Toshihiro, Ohnishi, Kazunori, Sakaida, Emiko, Fujisawa, Shin, Kobayashi, Yukio, Asou, Norio, Naoe, Tomoki, Kiyoi, Hitoshi, Miyazaki, Yasushi
المصدر: In Blood Advances June 2024
قاعدة البيانات: ScienceDirect
الوصف
تدمد:24739529
DOI:10.1182/bloodadvances.2024012655